Tenecteplase injection
Products billed under this code include Tnkase.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Tnkase.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Tnkase | Genentech, Inc. | 50242-0014-03 | 25 | $5,768.55 |
| Tnkase | Genentech, Inc. | 50242-0120-47 | 50 | $11,537.10 |
| Tnkase | Genentech, Inc. | 50242-0176-01 | 50 | $11,537.10 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $230.742 | +$13.321 | 1 MG | Tenecteplase injection | v1, posted September 17, 2026 |
| 3Q26 | $217.421 | +$19.98 | 1 MG | Tenecteplase injection | v1, posted September 15, 2026 |
| 2Q26 | $197.441 | +$10.469 | 1 MG | Tenecteplase injection | v1, posted September 15, 2026 |
| 1Q26 | $186.972 | +$14.751 | 1 MG | Tenecteplase injection | v1, posted September 15, 2026 |
| 4Q25 | $172.221 | +$0.283 | 1 MG | Tenecteplase injection | v1, posted September 8, 2026 |
| 3Q25 | $171.938 | +$9.482 | 1 MG | Tenecteplase injection | v1, posted March 10, 2026 |
| 2Q25 | $162.456 | +$0.025 | 1 MG | Tenecteplase injection | v1, posted March 10, 2026 |
| 1Q25 | $162.431 | +$4.707 | 1 MG | Tenecteplase injection | v1, posted December 19, 2025 |
| 4Q24 | $157.724 | +$0.256 | 1 MG | Tenecteplase injection | v1, posted June 11, 2025 |
| 3Q24 | $157.468 | +$4.356 | 1 MG | Tenecteplase injection | v1, posted June 11, 2025 |
| 2Q24 | $153.112 | −$0.002 | 1 MG | Tenecteplase injection | v1, posted March 11, 2025 |
| 1Q24 | $153.114 | +$0.018 | 1 MG | Tenecteplase injection | v1, posted December 19, 2024 |
| 4Q23 | $153.096 | +$0.40 | 1 MG | Tenecteplase injection | v1, posted October 10, 2024 |
| 3Q23 | $152.696 | +$9.004 | 1 MG | Tenecteplase injection | v1, posted June 5, 2024 |
| 2Q23 | $143.692 | +$0.041 | 1 MG | Tenecteplase injection | v1, posted February 23, 2024 |
| 1Q23 | $143.651 | −$0.221 | 1 MG | Tenecteplase injection | v1, posted December 6, 2023 |
| 4Q22 | $143.872 | +$4.392 | 1 MG | Tenecteplase injection | v1, posted June 22, 2023 |
| 3Q22 | $139.48 | +$4.721 | 1 MG | Tenecteplase injection | v1, posted June 9, 2023 |
| 2Q22 | $134.759 | +$0.138 | 1 MG | Tenecteplase injection | v1, posted December 14, 2022 |
| 1Q22 | $134.621 | −$0.116 | 1 MG | Tenecteplase injection | v1, posted June 8, 2022 |
| 4Q21 | $134.737 | −$0.07 | 1 MG | Tenecteplase injection | v1, posted June 2, 2022 |
| 3Q21 | $134.807 | +$5.639 | 1 MG | Tenecteplase injection | v1, posted June 2, 2022 |
| 2Q21 | $129.168 | −$0.106 | 1 MG | Tenecteplase injection | v1, posted March 1, 2022 |
| 1Q21 | $129.274 | – | 1 MG | Tenecteplase injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.